Akouos, a genetic medicine company, has leased 37,500 sf in Boston for its research headquarters. The facility is located in a two-story, 150,000-sf building at 645 Summer Street and will support the discovery and commercialization of therapies for hearing disorders. The project was developed by Pappas Enterprises and renovated by Tocci Building Corporation. The sustainably designed structure has attained LEED Silver certification.
Rosalind Franklin University is building the $50 million Innovation and Research Park in North Chicago, Ill. The four-story, 100,000-sf facility will provide leading-edge research labs, business incubator space, meeting rooms, and common areas. The project will promote collaboration among faculty, industry scientists, and biotech entrepreneurs in order to accelerate the discovery and commercialization of new medical treatments and therapeutics.
Autolus Therapeutics has signed a long-term, full-building lease with Alexandria Real Estate Equities for the construction and development of a build-to-suit facility in Rockville, Md. Located in the Shady Grove Life Sciences Center, the 85,000-sf project will accommodate the company's U.S. headquarters and a commercial-scale manufacturing center for cell therapies. Occupancy is expected in 2021.
Nagasaki University began construction in January of 2019 on a BSL-4 laboratory for the study of infectious diseases and pathogens in Japan. The $68 million biocontainment facility will support basic research to enable the development of innovative diagnosis, treatment, and prevention methods. The project is the first of its kind in the nation, although an existing BSL-4 lab at the National Institute of Infectious Diseases in Musashimurayama provides inspection and testing services. Research operations will begin at the Nagasaki facility in 2022.
EMD Serono is planning to construct a $70 million R&D facility on its existing campus in Billerica, Mass. Supporting research programs in oncology, immuno-oncology, and immunology, the 145,000-sf building will accommodate wet labs, offices, collaboration spaces, and a cafeteria. Designed to attain LEED and WELL certification, the project will provide a healthy and sustainable environment for approximately 400 employees. Completion is expected in 2021. EMD Serono is the biopharmaceutical business of Merck KGaA, based in Darmstadt, Germany.
Stellenbosch University began construction in January of 2019 on the $75 million Biomedical Research Institute in Cape Town, South Africa. Providing leading-edge research facilities for the Faculty of Medicine and Health Sciences, the integrated complex will include a bioinformatics hub, a clinical research unit, a biorepository, conference rooms, and labs for proteomics, electron microscopy, and flow cytometry.
Masonic Medical Research Institute is constructing a large-animal research facility in its existing building in Utica, N.Y. The $15 million project includes the renovation of a 5,500-sf basement to provide lab space for five investigators and a procedural suite for studies on pigs, sheep, goats, and rabbits. The investment will also support the recruitment of up to 30 new employees.
Ohio State University began construction in January of 2019 on the $59 million Biomedical and Materials Engineering Complex in Columbus. Featuring interactive laboratories for experiential learning, the five-story, 124,000-sf facility will provide an atrium, a 150-seat auditorium, two undergraduate computer labs, five classrooms, and open lab neighborhoods for faculty and graduate research.
Global life science company Promega is constructing a $190 million research and development center on its existing campus in Fitchburg, Wis. Offering laboratories with sophisticated infrastructure to support the creation of innovative bioscience products and technologies, the three-story, 270,000-sf facility will enable the consolidation of operations currently located in three separate buildings. Ground was broken on the project in July of 2018 and occupancy is expected in fall of 2020.
Brammer Bio is developing two gene therapy manufacturing facilities in Massachusetts. The company will build out 35,000 sf in an existing 50,000-sf structure in Lexington to create a cGMP manufacturing and quality control operations center. Additionally, Brammer will renovate 8,000 sf in its 66,000-sf commercial cGMP plant in Cambridge to create new production suites to support manufacturing capacity expansion. DPS Group is providing architectural and engineering services for both projects, which are slated for completion in mid-2019.
Fujifilm Cellular Dynamics is creating a stem cell manufacturing center in Madison, Wis. Located in the University Research Park, the $21 million project involves the renovation of 31,500 sf in a facility near the company's existing lab and office building. The completed biomanufacturing plant will meet the requirements of the U.S. Food and Drug Administration. Completion is expected by March of 2020.
The University of Texas Health Science Center at Houston opened a $15 million facility for the School of Biomedical Informatics in December of 2018. Located in the Texas Medical Center, the two-story, 44,709-sf project is the first freestanding school of biomedical informatics in the United States and was constructed on top of an existing parking garage.
Sanofi announced the lease of 900,000 sf in two buildings in the Cambridge Crossing development in December of 2018. The French pharmaceutical manufacturer will occupy approximately a fifth of the 45-acre campus spanning Cambridge, Boston, and Somerville. The project will provide collaborative laboratory and office space for 2,700 Sanofi employees.
16 Tech Community Corporation broke ground in December of 2018 on the $30 million Advanced Research and Innovation Facility in Indianapolis. The Indiana Biosciences Research Institute will lease over 67,000 sf on the first three floors of the building to accommodate researchers engaged in the study of diabetes, nutrition, and metabolics. Indiana University School of Medicine will locate the Center for Regenerative Medicine's molecular therapeutics program in 12,000 sf of the facility, which will also house the Central Indiana Corporate Partnership.
The Pirbright Institute will begin construction in early 2019 on the £50 million Brooksby Building in the United Kingdom. Designed to promote interaction and collaboration between investigators, the 51,000-sf facility will feature sophisticated biocontainment laboratories for the detection, diagnosis, and study of zoonotic diseases and livestock pathogens, as well as providing small animal vivarium space for in vivo research programs. The general contractor for the project is Kier and occupancy is expected by 2021.
